Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives $15.00 Consensus Price Target from Brokerages

Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) have earned a consensus recommendation of “Hold” from the nine brokerages that are presently covering the company, Marketbeat reports. Eight analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1 year price target among analysts that have covered the stock in the last year is $13.00.

A number of research firms recently weighed in on VIGL. Guggenheim set a $8.00 price objective on shares of Vigil Neuroscience and gave the stock a “neutral” rating in a report on Thursday. Jefferies Financial Group cut shares of Vigil Neuroscience to a “hold” rating in a report on Thursday. William Blair cut shares of Vigil Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Thursday. JMP Securities reaffirmed a “market perform” rating on shares of Vigil Neuroscience in a report on Thursday. Finally, Mizuho cut shares of Vigil Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Friday.

Hedge Funds Weigh In On Vigil Neuroscience

Large investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC boosted its position in shares of Vigil Neuroscience by 53.0% during the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company’s stock valued at $41,000 after purchasing an additional 8,358 shares in the last quarter. Jane Street Group LLC purchased a new stake in Vigil Neuroscience during the fourth quarter valued at about $83,000. Barclays PLC lifted its stake in Vigil Neuroscience by 43.6% during the fourth quarter. Barclays PLC now owns 64,049 shares of the company’s stock valued at $109,000 after buying an additional 19,436 shares in the last quarter. Northern Trust Corp lifted its stake in Vigil Neuroscience by 29.0% during the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company’s stock valued at $110,000 after buying an additional 14,572 shares in the last quarter. Finally, Two Sigma Advisers LP lifted its stake in Vigil Neuroscience by 243.8% during the fourth quarter. Two Sigma Advisers LP now owns 69,100 shares of the company’s stock valued at $117,000 after buying an additional 49,000 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Vigil Neuroscience Stock Performance

Shares of NASDAQ:VIGL opened at $7.89 on Friday. The stock has a market capitalization of $368.24 million, a price-to-earnings ratio of -3.83 and a beta of 1.90. Vigil Neuroscience has a 1-year low of $1.31 and a 1-year high of $7.95. The company’s fifty day moving average is $2.19 and its two-hundred day moving average is $2.28.

Vigil Neuroscience (NASDAQ:VIGL) last issued its earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. Sell-side analysts expect that Vigil Neuroscience will post -2.07 EPS for the current fiscal year.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.